Abstract
Purpose: Prostate adenocarcinoma is effectively treated with low dose rate brachytherapy. Acute and chronic urinary toxicity is the most common side effect associated with prostate brachytherapy (PB). Techniques to reduce this toxicity while maintaining efficacy of cancer control would certainly be beneficial. We plan our PB to intentionally limit dose to the bladder neck, as we have previously reported bladder neck dose to be the only correlative to acute and chronic urinary toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
